J4D:FRA
켄뷰
€14.50
arrow_downward
-1.96%(-0.29) 1D
4월 30일, 오후 10시 0분 0초 GMT+2 · EUR
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoJ4D의 주요 통계 생성 중...
시가
€14.34
고가
€14.50
저가
€14.34
시가총액
333.20억
평균 거래량
96.00
거래량
0.00
52주 최고가
€22.20
52주 최저가
€11.83
직원 수
2만
뉴스 기사
웹 소스 기반
MarketBeat
·
4시간 전
Kenvue Inc. $KVUE Shares Purchased by Wealthfront Advisers LLC
Barchart.com
·
3일 전
Kenvue Stock: Is Wall Street Bullish or Bearish?
프로필
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia
켄뷰에 관한 정보